Metformin trial for prostate cancer
Australian doctors have started recruiting metastatic prostate cancer patients for a pilot study to evaluate the benefits of metformin during androgen deprivation therapy (ADT).
They believe the drug could delay treatment resistance and are seeking patients who have not had hormonal treatment and are scheduled to start ADT.
This is based on the idea that the side effects of ADT, such as obesity and high levels of insulin, contribute to treatment resistance.
Dr Handoo Rhee, a urology research fellow from the Princess Alexandra